Faster approach for starting extended-release naltrexone to treat opioid use disorder shown effective
Faster approach for starting extended-release naltrexone to treat opioid use disorder shown effective
NIH-supported clinical trial addresses important barrier to opioid use disorder treatment.
Starting people with opioid use disorder on extended-release, injectable naltrexone (XR-naltrexone) within five to seven days of seeking treatment is more effective than the standard treatment method of starting within 10-15 days, but requires closer medical supervision, according to results from a clinical trialsupported by the National Institutes of Health’s (NIH) National Institute on Drug Abuse (NIDA). Published in JAMA Network Open, the findings suggest that this rapid treatment protocol could make XR-naltrexone more viable as a treatment option for opioid use disorder, which continues to take lives at an alarming rate. (NIH, USA, 08.05.2024)
https://nida.nih.gov/news-events/news-releases/2024/05/faster-approach-for-starting-extended-release-naltrexone-to-treat-opioid-use-disorder-shown-effective